Search

Abstract Parkinson’s Disease (PD) is a prevalent neurological condition characterized by motor and cognitive impairments, typically manifesting around the age of 50 and presenting symptoms such as gait difficulties and speech impairments. Although a cure remains elusive, symptom management through medication is possible. Timely detection is pivotal for effective disease management. In this study, we leverage Machine Learning (ML) and Deep Learning (DL) techniques, specifically K-Nearest Neighbor (KNN) and Feed-forward Neural Network (FNN) models, to differentiate between individuals with PD and healthy individuals based on voice signal characteristics. Our dataset, sourced from the University of California at Irvine (UCI), comprises 195 voice recordings collected from 31 patients. To optimize model performance, we employ various strategies including Synthetic Minority Over-sampling Technique (SMOTE) for addressing class imbalance, Feature Selection to identify the most relevant features, and hyperparameter tuning using RandomizedSearchCV. Our experimentation reveals that the FNN and KSVM models, trained on an 80–20 split of the dataset for training and testing respectively, yield the most promising results. The FNN model achieves an impressive overall accuracy of 99.11%, with 98.78% recall, 99.96% precision, and a 99.23% f1-score. Similarly, the KSVM model demonstrates strong performance with an overall accuracy of 95.89%, recall of 96.88%, precision of 98.71%, and an f1-score of 97.62%. Overall, our study showcases the efficacy of ML and DL techniques in accurately identifying PD from voice signals, underscoring the potential for these approaches to contribute significantly to early diagnosis and intervention strategies for Parkinson’s Disease.

Abstract Cervical cancer, the second most prevalent cancer affecting women, arises from abnormal cell growth in the cervix, a crucial anatomical structure within the uterus. The significance of early detection cannot be overstated, prompting the use of various screening methods such as Pap smears, colposcopy, and Human Papillomavirus (HPV) testing to identify potential risks and initiate timely intervention. These screening procedures encompass visual inspections, Pap smears, colposcopies, biopsies, and HPV-DNA testing, each demanding the specialized knowledge and skills of experienced physicians and pathologists due to the inherently subjective nature of cancer diagnosis. In response to the imperative for efficient and intelligent screening, this article introduces a groundbreaking methodology that leverages pre-trained deep neural network models, including Alexnet, Resnet-101, Resnet-152, and InceptionV3, for feature extraction. The fine-tuning of these models is accompanied by the integration of diverse machine learning algorithms, with ResNet152 showcasing exceptional performance, achieving an impressive accuracy rate of 98.08%. It is noteworthy that the SIPaKMeD dataset, publicly accessible and utilized in this study, contributes to the transparency and reproducibility of our findings. The proposed hybrid methodology combines aspects of DL and ML for cervical cancer classification. Most intricate and complicated features from images can be extracted through DL. Further various ML algorithms can be implemented on extracted features. This innovative approach not only holds promise for significantly improving cervical cancer detection but also underscores the transformative potential of intelligent automation within the realm of medical diagnostics, paving the way for more accurate and timely interventions.

Abstract Accurately classifying brain tumor types is critical for timely diagnosis and potentially saving lives. Magnetic Resonance Imaging (MRI) is a widely used non-invasive method for obtaining high-contrast grayscale brain images, primarily for tumor diagnosis. The application of Convolutional Neural Networks (CNNs) in deep learning has revolutionized diagnostic systems, leading to significant advancements in medical imaging interpretation. In this study, we employ a transfer learning-based fine-tuning approach using EfficientNets to classify brain tumors into three categories: glioma, meningioma, and pituitary tumors. We utilize the publicly accessible CE-MRI Figshare dataset to fine-tune five pre-trained models from the EfficientNets family, ranging from EfficientNetB0 to EfficientNetB4. Our approach involves a two-step process to refine the pre-trained EfficientNet model. First, we initialize the model with weights from the ImageNet dataset. Then, we add additional layers, including top layers and a fully connected layer, to enable tumor classification. We conduct various tests to assess the robustness of our fine-tuned EfficientNets in comparison to other pre-trained models. Additionally, we analyze the impact of data augmentation on the model's test accuracy. To gain insights into the model's decision-making, we employ Grad-CAM visualization to examine the attention maps generated by the most optimal model, effectively highlighting tumor locations within brain images. Our results reveal that using EfficientNetB2 as the underlying framework yields significant performance improvements. Specifically, the overall test accuracy, precision, recall, and F1-score were found to be 99.06%, 98.73%, 99.13%, and 98.79%, respectively.

Abstract The electroencephalogram (EEG) has emerged over the past few decades as one of the key tools used by clinicians to detect seizures and other neurological abnormalities of the human brain. The proper diagnosis of epilepsy is crucial due to its distinctive nature and the subsequent negative effects of epileptic seizures on patients. The classification of minimally pre-processed, raw multichannel EEG signal recordings is the foundation of this article’s unique method for identifying seizures in pre-adult patients. The new method makes use of the automatic feature learning capabilities of a three-dimensional deep convolution auto-encoder (3D-DCAE) associated with a neural network-based classifier to build an integrated framework that endures training in a supervised manner to attain the highest level of classification precision among brain state signals, both ictal and interictal. A pair of models were created and evaluated for testing and assessing our method, utilizing three distinct EEG data section lengths, and a tenfold cross-validation procedure. Based on five evaluation criteria, the labelled hybrid convolutional auto-encoder (LHCAE) model, which utilizes a classifier based on bidirectional long short-term memory (Bi-LSTM) and an EEG segment length of 4 s, had the best efficiency. This proposed model has 99.08 ± 0.54% accuracy, 99.21 ± 0.50% sensitivity, 99.11 ± 0.57% specificity, 99.09 ± 0.55% precision, and an F1-score of 99.16 ± 0.58%, according to the publicly available Children’s Hospital Boston (CHB) dataset. Based on the obtained outcomes, the proposed seizure classification model outperforms the other state-of-the-art method’s performance in the same dataset.

Abstract Heart disease is a significant global cause of mortality, and predicting it through clinical data analysis poses challenges. Machine learning (ML) has emerged as a valuable tool for diagnosing and predicting heart disease by analyzing healthcare data. Previous studies have extensively employed ML techniques in medical research for heart disease prediction. In this study, eight ML classifiers were utilized to identify crucial features that enhance the accuracy of heart disease prediction. Various combinations of features and well-known classification algorithms were employed to develop the prediction model. Neural network models, such as Naïve Bayes and Radial Basis Functions, were implemented, achieving accuracies of 94.78% and 90.78% respectively in heart disease prediction. Among the state-of-the-art methods for cardiovascular problem prediction, Learning Vector Quantization exhibited the highest accuracy rate of 98.7%. The motivation behind predicting Cardiovascular Heart Disease lies in its potential to save lives, improves health outcomes, and allocates healthcare resources efficiently. The key contributions encompass early intervention, personalized medicine, technological advancements, the impact on public health, and ongoing research, all of which collectively work toward reducing the burden of CHD on both individual patients and society as a whole.